TLDR
- Eli Lilly leads the obesity and diabetes drug market with Mounjaro and Zepbound, backed by a strong drug pipeline
- Abbott Laboratories runs a diversified healthcare business across devices, diagnostics, and nutrition
- Johnson & Johnson is focused on pharma and medical tech after spinning off its consumer health unit
- All three companies benefit from ageing populations and growing demand for advanced treatments
- Investors are rotating from expensive tech stocks into defensive healthcare names in 2026
Investors are taking a closer look at healthcare stocks in 2026 as money moves away from high-priced technology companies. Three names are drawing the most attention: Eli Lilly, Abbott Laboratories, and Johnson & Johnson.
Eli Lilly
Eli Lilly has become one of the biggest growth stories in healthcare.
The company leads the obesity and diabetes drug market through its GLP-1 treatments Mounjaro and Zepbound. Demand for these drugs continues to grow globally, and analysts expect them to stay major revenue drivers for years.
JPMorgan recently reaffirmed its positive outlook on the stock, pointing to growing Medicare adoption and continued momentum from obesity treatments.
Beyond weight loss, Lilly has a deep drug pipeline covering oncology, neuroscience, immunology, and metabolic disease. The company has invested heavily in manufacturing capacity and acquisitions to support that growth.
Lilly trades at a premium, but analysts say the valuation reflects one of the strongest earnings growth profiles in the pharmaceutical industry.
Abbott Laboratories
Abbott Laboratories takes a different approach from a pure-play drug company.
The company runs a diversified business across medical devices, diagnostics, nutrition, and established pharmaceuticals. That mix has helped it produce steady earnings through different economic conditions.
Abbott’s FreeStyle Libre glucose monitoring platform is a standout in diabetes care. Its cardiovascular devices and diagnostics units are also growing as global populations age and demand for healthcare rises.
The company generates reliable cash flow, which it uses to invest in new products and pay a steadily growing dividend.
Johnson & Johnson
Johnson & Johnson has sharpened its focus after separating its consumer health business.
The company now concentrates on pharmaceuticals and medical technology. Its oncology portfolio is growing, led by strong demand for Darzalex. The drug recently received European approval, and the company continues to expand its cancer treatment pipeline ahead of upcoming earnings.
Cardiovascular and surgical devices are also delivering healthy growth. Johnson & Johnson has raised its dividend for more than six decades, making it a reliable income stock for long-term holders.
Why These Three Stand Out
Healthcare is drawing investor interest for clear reasons. Ageing populations, rising demand for advanced treatments, and strong pharmaceutical pipelines are all driving the sector forward in 2026.
Eli Lilly offers the strongest growth potential. Abbott brings diversification and stability. Johnson & Johnson combines innovative medicines with one of the longest dividend growth records on the market.
Together, the three stocks give investors broad exposure to pharmaceuticals, medical devices, diagnostics, and defensive healthcare spending.
4th of July Flash Sale – 50% OFF!
Celebrate Independence Day by investing in your future. For a limited time, get 50% OFF a Knockout Stocks membership and unlock our latest high-conviction stock picks, powered by our proprietary KO Score algorithm.
You'll also get access to our long-term investment ideas and shorter-term trade opportunities, helping you identify potential opportunities before the crowd.
Sign up to Knockout Stocks today and get 50% OFF to unlock the full list of premium stock picks.
Use coupon code SPECIAL50 for your exclusive discount.
Offer ends soon. Don't miss out!
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
